Iron and manganese-related CNS toxicity: mechanisms, diagnosis and treatment

References

• Au C, Benedetto A, Aschner M. Manganese transport in eukaryotes: the role of DMT1. Neurotoxicology. 2008 Jul;29(4):569–576. PubMed PMID: 18565586; eng.
   PubMed Web of Science ®Google Scholar
• Aschner M, Aschner JL. Manganese transport across the blood-brain barrier: relationship to iron homeostasis. Brain Res Bull. 1990 Jun;24(6):857–860. 036s1-9230(90)90152-P [pii]. PubMed PMID: 2372703; eng.
   PubMed Web of Science ®Google Scholar
• Aschner M, Gannon M. Manganese (Mn) transport across the rat blood-brain barrier: saturable and transferrin-dependent transport mechanisms. Brain Res Bull. 1994;33(3): 345–349. 0361-9230(94)90204-6 [pii]. PubMed PMID: 8293318; eng.
   PubMed Web of Science ®Google Scholar
• Gunter TE, Gerstner B, Gunter KK, et al. Manganese transport via the transferrin mechanism. Neurotoxicology. 2013 Jan;34:118–127. PubMed PMID: 23146871; eng.
   PubMed Web of Science ®Google Scholar
• Sheftel AD, Zhang AS, Brown C, et al. Direct interorganellar transfer of iron from endosome to mitochondrion. Blood. 2007 Jul 1;110(1):125–132. PubMed PMID: 17376890; eng.
   PubMed Web of Science ®Google Scholar
• Yin Z, Jiang H, Lee ES, et al. Ferroportin is a manganese-responsive protein that decreases manganese cytotoxicity and accumulation. J Neurochem. 2010 Mar;112(5):1190–1198. PubMed PMID: 20002294; PubMed Central PMCID: PMCPMC2819584. eng.
   PubMed Web of Science ®Google Scholar
• Chifman J, Laubenbacher R, Torti SV. A systems biology approach to iron metabolism. In: Corey SJ, Kimmel M, Leonard JN, editors. A systems biology approach to blood. New York (NY): Springer New York; 2014. p. 201–225.
   Google Scholar
• Pantopoulos K, Porwal SK, Tartakoff A, et al. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51(29):5705–5724.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Iron metabolism: iron deficiency and iron overload. Annu Rev Genomics Hum Genet. 2000;11:75–98. PubMed PMID: 11701625.
   PubMedGoogle Scholar
• Chen P, Bornhorst J, Aschner M. Manganese metabolism in humans. Front Biosci (Landmark Ed). 2018;23:1655–1679.
   PubMed Web of Science ®Google Scholar
• Chen P, Miah MR, Aschner M Metals and neurodegeneration. F1000Research. 2016;5. 366
   Google Scholar
• Chen P, Chakraborty S, Mukhopadhyay S, et al. Manganese homeostasis in the nervous system. J Neurochem. 2015;134(4):601–610.
   PubMed Web of Science ®Google Scholar
• Zecca L, Youdim MBH, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863–873.
   PubMed Web of Science ®Google Scholar
• Mills E, Dong X-P, Wang F, et al. Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem. 2010;2(1):51. PubMed PMID: PMC2812924
   PubMed Web of Science ®Google Scholar
• Rivera-Mancía S, Ríos C, Montes S. Manganese accumulation in the CNS and associated pathologies [journal article]. Biometals. 2011 October 1;24(5):811–825.
   PubMed Web of Science ®Google Scholar
• Ward R, Zucca FA, Duyn JH, et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045–60.
   Google Scholar
• Khan FH, Ahlberg CD, Chow CA, et al. Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome [journal article]. J Neurol. 2017;1–8. DOI:10.1007/s00415-017-8431-1
   Web of Science ®Google Scholar
• Gonzalez-Reyes RE, Gutierrez-Alvarez AM, Moreno CB. Manganese and epilepsy: A systematic review of the literature. Brain Res Rev. 2007;53(2):332–336.
   PubMedGoogle Scholar
• Carl GF, Blackwell L, Barnett F, et al. Manganese and epilepsy: brain glutamine synthetase and liver arginase activities in genetically epilepsy prone and chronically seizured rats. Epilepsia. 1993;34(3):441–446.
   PubMed Web of Science ®Google Scholar
• Davidson D, Ward NI. Abnormal aluminium, cobalt, manganese, strontium and zinc concentrations in untreated epilepsy. Epilepsy Res. 1988;2(5):323–330.
   PubMed Web of Science ®Google Scholar
• Carl G, Keen C, Gallagher B, et al. Association of low blood manganese concentrations with epilepsy. Neurology. 1986;36(12):1584.
   PubMed Web of Science ®Google Scholar
• Paul BT, Manz DH, Torti FM, et al. Mitochondria and iron: current questions. Expert Rev Hematol. 2017 Dec 12;10(1):65–79. PubMed PMID: PMC5538026.
   PubMed Web of Science ®Google Scholar
• Pantopoulos K, Porwal SK, Tartakoff A, et al. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012 Jul 24;51(29):5705–5724. PubMed PMID: 22703180; PubMed Central PMCID: PMCPMC3572738.
   PubMed Web of Science ®Google Scholar
• Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005 Jan 15;202(2):199–211. PubMed PMID: 15629195.
   PubMed Web of Science ®Google Scholar
• Piñero D, Connor J. Iron in the brain: an important contributor in normal and diseased states. The Neuroscientist. 2000; 6(6), 435–453.
   Google Scholar
• Hare D, Ayton S, Bush A, et al. A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci. 2013 Jul 18;5:34.
   Google Scholar
• Oppenheimer, Beard, Lozoff, et al. Iron biology in immune function, muscle metabolism and neuronal functioning. Discussion. J Nutr. 2001 Feb;131(2S-2):568S–579S; discussion 580S.
   Google Scholar
• Todorich B, Pasquini JM, Garcia CI, et al. Oligodendrocytes and myelination: the role of Iron. Glia. 2009 Apr 1;57(5):467–78.
   Google Scholar
• Zecca L, Youdim MBH, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders [Review Article]. Nat Rev Neurosci. 2004 Jan 11;5:863.
   PubMed Web of Science ®Google Scholar
• de Lima MN, Polydoro M, Laranja, DC, et al. Recognition memory impairment and brain oxidative stress induced by postnatal iron administration. Eur J Neurosci. 2005;21(9):2521–2528.
   PubMed Web of Science ®Google Scholar
• Dal-Pizzol F, Klamt F, Frota MLC, et al. Neonatal iron exposure induces oxidative stress in adult Wistar rat. Brain Res Dev Brain Res. 2001 Sep 23;130(1):109–14.
   Google Scholar
• Piloni NE, Fermandez V, Videla LA, et al. Acute iron overload and oxidative stress in brain. Toxicology. 2013;314(1):174–182.
   PubMed Web of Science ®Google Scholar
• Ilaria P, Romina M, Francesco MM, et al. Iron handling in hippocampal neurons: activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell. 2011;10(1):172–183.
   PubMed Web of Science ®Google Scholar
• Sripetchwandee J, Sanit J, Chattipakorn N, et al. Mitochondrial calcium uniporter blocker effectively prevents brain mitochondrial dysfunction caused by iron overload. Life Sci. 2013;92(4):298–304.
   PubMed Web of Science ®Google Scholar
• Crichton R. Iron metabolism: from molecular mechanisms to clinical consequences. Chicester, UK: John Wiley & Sons, Incorporated; 2016.
   Google Scholar
• Chua A, Morgan E. Effects of iron deficiency and iron overload on manganese uptake and deposition in the brain and other organs of the rat. Biol Trace Elem Res. 1996 Oct-Nov;55(1-2):39–54.
   Google Scholar
• Greenough MA, Camakaris J, Bush AI. Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int. 2013;62(5):540–555.
   PubMed Web of Science ®Google Scholar
• Lee DL, Strathmann FG, Walton J, et al. Iron deficiency disrupts axon maturation of the developing auditory nerve. J Neurosci. 2012;32(14):5010–5015. PubMed PMID: PMC3327472.
   PubMed Web of Science ®Google Scholar
• Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med. 2004 Jul;5(4):385–391. PubMed PMID: 15222997.
   PubMed Web of Science ®Google Scholar
• Batra J, Sood A. Iron deficiency anaemia: effect on congnitive development in children: A review. Indian J Clin Biochem. 2005;20(2):119–125. PubMed PMID: PMC3453858.
   PubMedGoogle Scholar
• Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011 Jan;26(1):114–120. PubMed PMID: 21322022; eng.
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003 Mar;4(2):101–119. S1389945703000108 [pii]. PubMed PMID: 14592341; eng.
   PubMed Web of Science ®Google Scholar
• Wagner ML, Walters AS, Fisher BC. Symptoms of attention-deficit/hyperactivity disorder in adults with restless legs syndrome. Sleep. 2004 Dec 15;27(8):1499–1504. PubMed PMID: 15683140; eng.
   PubMed Web of Science ®Google Scholar
• Li Y, Walters AS, Chiuve SE, et al. Prospective study of restless legs syndrome and coronary heart disease among women. Circulation. 2012 Oct 2;126(14):1689–1694. PubMed PMID: 22967852; PubMed Central PMCID: PMC3493117. eng.
   PubMed Web of Science ®Google Scholar
• Pennestri MH, Montplaisir J, Colombo R, et al. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology. 2007 Apr 10;68(15):1213–1218. PubMed PMID: 17420405; eng.
   PubMed Web of Science ®Google Scholar
• Siddiqui F, Strus J, Ming X, et al. Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol. 2007 Sep;118(9):1923–1930. S1388-2457(07)00199-X [pii]. PubMed PMID: 17588809; eng
   PubMed Web of Science ®Google Scholar
• Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep. 2009 May;32(5):589–597. PubMed PMID: 19480225; PubMed Central PMCID: PMC2675893. eng.
   PubMed Web of Science ®Google Scholar
• Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord. 2007;22 Suppl 18:S440–8. PubMed PMID: 17566122.
   PubMed Web of Science ®Google Scholar
• Connor JR. Pathophysiology of restless legs syndrome: evidence for iron involvement. Curr Neurol Neurosci Rep. 2008 Mar;8(2):162–166. PubMed PMID: 18460286; eng.
   PubMed Web of Science ®Google Scholar
• Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of sleep medicine clinical practice guideline. Sleep. 2012 Aug;35(8):1039–1062. PubMed PMID: 22851801; PubMed Central PMCID: PMC3397811. eng.
   PubMed Web of Science ®Google Scholar
• Cho YW, Allen RP, Earley CJ. Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep Med. 2013 Jan17. [pii] S1389-9457(12)00400-5. PubMed PMID: 23333678; Eng. DOI:10.1016/j.sleep.2012.11.001
   Google Scholar
• Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med. 2010 May;11(5):494–496. PubMed PMID: 20371212; eng.
   PubMed Web of Science ®Google Scholar
• Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. J Neurochem. 2016 Oct;139(Suppl 1):179–197. PubMed PMID: 26545340.
   PubMedGoogle Scholar
• Li Y, Jiao Q, Xu H, et al. Biometal dyshomeostasis and toxic metal accumulations in the development of Alzheimer’s disease. Front Mol Neurosci. 2017;10:339. PubMed PMID: 29114205; PubMed Central PMCID: PMCPMC5660707.
   PubMed Web of Science ®Google Scholar
• Cheignon C, Tomas M, Bonnefont-Rousselot D, et al. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018 Apr;14:450–464. PubMed PMID: 29080524; PubMed Central PMCID: PMCPMC5680523.
   PubMed Web of Science ®Google Scholar
• Uranga RM, Salvador GA. Unraveling the burden of iron in neurodegeneration: intersections with amyloid beta peptide pathology. Oxid Med Cell Longev. 2018;2018:2850341. PubMed PMID: 29581821; PubMed Central PMCID: PMCPMC5831758.
   PubMedGoogle Scholar
• Cristovao JS, Santos R, Gomes CM. Metals and neuronal metal binding proteins implicated in Alzheimer’s disease. Oxid Med Cell Longev. 2016;2016:9812178. PubMed PMID: 26881049; PubMed Central PMCID: PMCPMC4736980.
   PubMedGoogle Scholar
• Li K, Reichmann H. Role of iron in neurodegenerative diseases. J Neural Transm (Vienna). 2016 Apr;123(4):389–399. PubMed PMID: 26794939.
   PubMed Web of Science ®Google Scholar
• Balejcikova L, Siposova K, Kopcansky P, et al. Fe(II) formation after interaction of the amyloid beta-peptide with iron-storage protein ferritin. J Biol Phys. 2018 May 9 PubMed PMID: 29740739; PubMed Central PMCID: PMCPMC6082800. DOI:10.1007/s10867-018-9498-3
   PubMed Web of Science ®Google Scholar
• Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272.
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang J, Rogers J, et al. Brain iron metabolism dysfunction in Parkinson’s disease. Mol Neurobiol. 2017 May;54(4):3078–3101. PubMed PMID: 27039308.
   PubMed Web of Science ®Google Scholar
• Hare DJ, Double KL. Iron and dopamine: a toxic couple. Brain. 2016 Apr;139(Pt 4):1026–1035. PubMed PMID: 26962053.
   PubMedGoogle Scholar
• Song N, Xie J. Iron, dopamine, and alpha-synuclein interactions in at-risk dopaminergic neurons in Parkinson’s disease. Neurosci Bull. 2018 Apr;34(2):382–384. PubMed PMID: 29380248; PubMed Central PMCID: PMCPMC5856725.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Miah M, Culbreth M, et al. Autophagy in neurodegenerative diseases and metal neurotoxicity. Neurochem Res. 2016 Feb;41(1–2):409–422. PubMed PMID: 26869037.
   PubMed Web of Science ®Google Scholar
• Gorell JM, Peterson EL, Rybicki BA, et al. Multiple risk factors for Parkinson’s disease. J Neurol Sci. 2004;217(2):169–174.
   PubMed Web of Science ®Google Scholar
• Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson’s disease progression. Oxid Med Cell Longev. 2017;2017:6405278. PubMed PMID: 29081890; PubMed Central PMCID: PMCPMC5610862.
   PubMed Web of Science ®Google Scholar
• Lan AP, Chen J, Chai ZF, et al. The neurotoxicity of iron, copper and cobalt in Parkinson’s disease through ROS-mediated mechanisms. Biometals. 2016 Aug;29(4):665–678. PubMed PMID: 27349232.
   PubMed Web of Science ®Google Scholar
• Lingor P, Carboni E, Koch JC. Alpha-synuclein and iron: two keys unlocking Parkinson’s disease. J Neural Transm (Vienna). 2017 Aug;124(8):973–981. PubMed PMID: 28168622.
   PubMed Web of Science ®Google Scholar
• Moreau C, Duce JA, Rascol O, et al. Iron as a therapeutic target for Parkinson’s disease. Mov Disord. 2018 Apr;33(4):568–574. PubMed PMID: 29380903.
   PubMed Web of Science ®Google Scholar
• Munoz Y, Carrasco CM, Campos JD, et al. Parkinson’s disease: the mitochondria-iron link. Parkinsons Dis. 2016;2016:7049108. PubMed PMID: 27293957; PubMed Central PMCID: PMCPMC4886095.
   PubMedGoogle Scholar
• Song N, Wang J, Jiang H, et al. Astroglial and microglial contributions to iron metabolism disturbance in Parkinson’s disease. Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):967–973. PubMed PMID: 29317336.
   PubMed Web of Science ®Google Scholar
• Xu H, Wang Y, Song N, et al. New progress on the role of glia in iron metabolism and iron-induced degeneration of dopamine neurons in Parkinson’s disease. Front Mol Neurosci. 2017:10:455. PubMed PMID: 29403352; PubMed Central PMCID: PMCPMC5780449.
   PubMed Web of Science ®Google Scholar
• Biasiotto G, Di Lorenzo D, Archetti S, et al. Iron and Neurodegeneration: is Ferritinophagy the Link? Mol Neurobiol. 2016 Oct;53(8):5542–5574. PubMed PMID: 26468157.
   PubMed Web of Science ®Google Scholar
• Guiney SJ, Adlard PA, Bush AI, et al. Ferroptosis and cell death mechanisms in Parkinson’s disease. Neurochem Int. 2017 Mar;104:34–48. PubMed PMID: 28082232.
   PubMed Web of Science ®Google Scholar
• Chiang S, Kalinowski DS, Jansson PJ, et al. Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich’s ataxia. Neurochem Int. 2018 Jul;117:35–48. PubMed PMID: 28782591.
   PubMed Web of Science ®Google Scholar
• Lupoli F, Vannocci T, Longo G, et al. The role of oxidative stress in Friedreich’s ataxia. FEBS Lett. 2018 Mar;592(5):718–727. PubMed PMID: 29197070; PubMed Central PMCID: PMCPMC5887922.
   PubMed Web of Science ®Google Scholar
• Burk K. Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias. 2017;4:4. PubMed PMID: 28405347; PubMed Central PMCID: PMCPMC5383992.
   PubMedGoogle Scholar
• Ghosh R, Tabrizi SJ. Clinical features of Huntington’s disease. In: Pereira NC, de Almeida L, editors. Polyglutamine disorders. Cham: Springer International Publishing; 2018. p. 1–28.
   Google Scholar
• Jimenez-Sanchez M, Licitra F, Underwood BR, et al. Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017 Jul 1;7(7). DOI:10.1101/cshperspect.a024240
   PubMed Web of Science ®Google Scholar
• Agrawal S, Fox J, Thyagarajan B, et al. Brain mitochondrial iron accumulates in Huntington’s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. Free Radic Biol Med. 2018 May;20(120):317–329. PubMed PMID: 29625173; PubMed Central PMCID: PMCPMC5940499.
   PubMed Web of Science ®Google Scholar
• Muller M, Leavitt BR. Iron dysregulation in Huntington’s disease. J Neurochem. 2014 Aug;130(3):328–350. PubMed PMID: 24717009.
   PubMed Web of Science ®Google Scholar
• Horning KJ, Caito SW, Tipps KG, et al. Manganese is essential for neuronal health. Annu Rev Nutr. 2015;35(1):71–108. PubMed PMID: 25974698.
   PubMedGoogle Scholar
• Rosas H, Chen Y, Doros G, et al. Alterations in brain transition metals in huntington disease: an evolving and intricate story. Arch Neurol. 2012;69(7):887–893.
   PubMedGoogle Scholar
• Bowman AB, Kwakye GF, Herrero Hernández E, et al. Role of manganese in neurodegenerative diseases. J Trace Elem Med Biol. 2011;25(4):191–203.
   PubMed Web of Science ®Google Scholar
• Bryan MR, Bowman AB. Manganese and the insulin-IGF signaling network in Huntington’s disease and other neurodegenerative disorders. In: Aschner M, Costa LG, editors. Neurotoxicity of metals. Cham: Springer International Publishing; 2017. p. 113–142.
   Google Scholar
• Sepers MD, Raymond LA. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington’s disease. Drug Discov Today. 2014;19(7):990–996.
   PubMed Web of Science ®Google Scholar
• Zanardi A, Conti A, Cremonesi M, et al. Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. EMBO Mol Med. 2018 Jan;10(1):91–106. PubMed PMID: 29183916; PubMed Central PMCID: PMCPMC5760856.
   PubMed Web of Science ®Google Scholar
• Kono S. Aceruloplasminemia: an update. Int Rev Neurobiol. 2013;110:125–151. PubMed PMID: 24209437.
   PubMed Web of Science ®Google Scholar
• Miyajima H. Aceruloplasminemia. Neuropathology. 2015 Feb;35(1):83–90. PubMed PMID: 25168455.
   PubMed Web of Science ®Google Scholar
• Levi S, Finazzi D. Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front Pharmacol. 2014;5:99. PubMed PMID: 24847269; PubMed Central PMCID: PMCPMC4019866.
   PubMed Web of Science ®Google Scholar
• Meyer E, Kurian MA, Hayflick SJ. Neurodegeneration with brain iron accumulation: genetic diversity and pathophysiological mechanisms. Annu Rev Genomics Hum Genet. 2015;16:257–279. PubMed PMID: 25973518.
   PubMed Web of Science ®Google Scholar
• Keogh MJ, Jonas P, Coulthard A, et al. Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics. 2012 Feb;13(1):93–96. PubMed PMID: 22278127; PubMed Central PMCID: PMCPMC4038507.
   PubMed Web of Science ®Google Scholar
• Kumar N, Rizek P, Jog M. Neuroferritinopathy: pathophysiology, presentation, differential diagnoses and management. Tremor Other Hyperkinet Mov (N Y). 2016;6:355. PubMed PMID: 27022507; PubMed Central PMCID: PMCPMC4795517.
   PubMed Web of Science ®Google Scholar
• Levi S, Rovida E. Neuroferritinopathy: from ferritin structure modification to pathogenetic mechanism. Neurobiol Dis. 2015 Sep;81:134–143. PubMed PMID: 25772441; PubMed Central PMCID: PMCPMC4642653.
   PubMed Web of Science ®Google Scholar
• Garringer HJ, Irimia JM, Li W, et al. Effect of systemic iron overload and a chelation therapy in a mouse model of the neurodegenerative disease hereditary ferritinopathy. PLoS One. 2016;11(8):e0161341. PubMed PMID: 27574973; PubMed Central PMCID: PMCPMC5004847.
   PubMed Web of Science ®Google Scholar
• Hogarth P, Kurian MA, Gregory A, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab. 2017 Mar;120(3):278–287. PubMed PMID: 28034613.
   PubMed Web of Science ®Google Scholar
• Di Meo I, Carecchio M, Tiranti V. Inborn errors of coenzyme A metabolism and neurodegeneration. J Inherit Metab Dis. 2018 May 16. PubMed PMID: 29767814. DOI:10.1007/s10545-018-0193-0
   PubMed Web of Science ®Google Scholar
• Orellana DI, Santambrogio P, Rubio A, et al. Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration. EMBO Mol Med. 2016 Oct;8(10):1197–1211. PubMed PMID: 27516453; PubMed Central PMCID: PMCPMC5048368.
   PubMed Web of Science ®Google Scholar
• Drecourt A, Babdor J, Dussiot M, et al. Impaired transferrin receptor palmitoylation and recycling in neurodegeneration with brain iron accumulation. Am J Hum Genet. 2018 Feb 1;102(2):266–277. PubMed PMID: 29395073; PubMed Central PMCID: PMCPMC5985451.
   PubMed Web of Science ®Google Scholar
• Dusek P, Schneider SA, Aaseth J. Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol. 2016 Dec;38:81–92. PubMed PMID: 27033472.
   PubMed Web of Science ®Google Scholar
• Aaseth J, Alexander J, Bjorklund G, et al. Treatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation. Biometals. 2016 Oct;29(5):827–839. PubMed PMID: 27530256; PubMed Central PMCID: PMCPMC5034004.
   PubMed Web of Science ®Google Scholar
• Adlard PA, Bush AI. Metals and Alzheimer’s disease: how far have we come in the clinic? J Alzheimers Dis. 2018;62(3):1369–1379. PubMed PMID: 29562528; PubMed Central PMCID: PMCPMC5870044.
   PubMed Web of Science ®Google Scholar
• Amit T, Bar-Am O, Mechlovich D, et al. The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer’s disease models. Neuropharmacology. 2017 Sep;1(123):359–367. PubMed PMID: 28571715.
   PubMed Web of Science ®Google Scholar
• Oliveri V, Vecchio G. Prochelator strategies for site-selective activation of metal chelators. J Inorg Biochem. 2016 Sep;162:31–43. PubMed PMID: 27297691.
   PubMed Web of Science ®Google Scholar
• Monacelli F, Acquarone E, Giannotti C, et al. Vitamin C, aging and Alzheimer’s disease. Nutrients. 2017 Jun 27;9(7). PubMed PMID: 28654021; PubMed Central PMCID: PMCPMC5537785. DOI:10.3390/nu9070670.
   PubMed Web of Science ®Google Scholar
• Lang AE, Espay AJ. Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord. 2018 May;33(5):660–677. PubMed PMID: 29644751.
   PubMed Web of Science ®Google Scholar
• Maiti P, Dunbar GL. Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci. 2018 May 31;19(6). PubMed PMID: 29857538; PubMed Central PMCID: PMCPMC6032333. DOI:10.3390/ijms19061637.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang Y, Quan Z, et al. Epigallocatechin Gallate (EGCG) inhibits alpha-synuclein aggregation: a potential agent for Parkinson’s disease. Neurochem Res. 2016 Oct;41(10):2788–2796. PubMed PMID: 27364962.
   PubMed Web of Science ®Google Scholar
• Costa C, Tsatsakis A, Mamoulakis C, et al. Current evidence on the effect of dietary polyphenols intake on chronic diseases. Food Chem Toxicol. 2017 Dec;110:286–299. PubMed PMID: 29042289.
   PubMed Web of Science ®Google Scholar
• Smith LM, Parr-Brownlie LC. A neuroscience perspective of the gut theory of Parkinson’s disease. Eur J Neurosci. 2018 Feb 15. PubMed PMID: 29446158. DOI:10.1111/ejn.13869.
   Web of Science ®Google Scholar
• Aranca TV, Jones TM, Shaw JD, et al. Emerging therapies in Friedreich’s ataxia. Neurodegener Dis Manag. 2016 Feb;6(1):49–65.
   PubMed Web of Science ®Google Scholar
• Kieburtz K, Reilmann R, Olanow CW. Huntington’s disease: current and future therapeutic prospects. Mov Disord. 2018 Jul;33(7):1033–1041. PubMed PMID: 29737569.
   PubMed Web of Science ®Google Scholar
• Dickey AS, La Spada AR. Therapy development in Huntington disease: from current strategies to emerging opportunities. Am J Med Genet A. 2018 Apr;176(4):842–861. PubMed PMID: 29218782; PubMed Central PMCID: PMCPMC5975251.
   PubMed Web of Science ®Google Scholar
• Poli L, Alberici A, Buzzi P, et al. Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment. Neurol Sci. 2017 Feb;38(2):357–360. PubMed PMID: 27817091.
   PubMed Web of Science ®Google Scholar
• Fernsebner K, Zorn J, Kanawati B, et al. Manganese leads to an increase in markers of oxidative stress as well as to a shift in the ratio of Fe(ii)/(iii) in rat brain tissue [10.1039/C4MT00022F]. Metallomics. 2014;6(4):921–931.
   PubMed Web of Science ®Google Scholar
• Stamelou M, Tuschl K, Chong WK, et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: A new treatable disorder. Mov Disord. 2012;27(10):1317–1322.
   PubMed Web of Science ®Google Scholar
• Tuschl K, Clayton PT, Gospe SM Jr., et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2012 Mar 9;90(3):457–466. PubMed PMID: 22341972; PubMed Central PMCID: PMC3309187.
   PubMed Web of Science ®Google Scholar
• Quadri M, Federico A, Zhao T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012;90(3):467–477.
   PubMed Web of Science ®Google Scholar
• Gunter TE, Gerstner B, Lester T, et al. An analysis of the effects of Mn2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol Appl Pharmacol. 2010 Nov 15;249(1):65–75. PubMed PMID: 20800605; PubMed Central PMCID: PMC3004221.
   PubMed Web of Science ®Google Scholar
• Roth JA, Feng L, Walowitz J, et al. Manganese‐induced rat pheochromocytoma (PC12) cell death is independent of caspase activation. J Neurosci Res. 2000;61(2):162–171.
   PubMed Web of Science ®Google Scholar
• Malecki EA. Manganese toxicity is associated with mitochondrial dysfunction and DNA fragmentation in rat primary striatal neurons. Brain Res Bull. 2001 May 15;55(2):225–228.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cao R, Cai T, et al. The role of autophagy dysregulation in manganese-induced dopaminergic neurodegeneration. Neurotox Res. 2013 Nov 1. 244:478–490. English.
   PubMed Web of Science ®Google Scholar
• Schrantz N, Blanchard DA, Mitenne F, et al. Manganese induces apoptosis of human B cells: caspase-dependent cell death blocked by bcl-2. Cell Death Differ. 1999;6(5):445–453.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Adachi K, Kiuchi K. Activation of JNK pathway and induction of apoptosis by manganese in PC12 cells. J Neurochem. 1998;71(4):1607–1615.
   PubMed Web of Science ®Google Scholar
• Angeli S, Barhydt T, Jacobs R, et al. Manganese disturbs metal and protein homeostasis in Caenorhabditis elegans [10.1039/C4MT00168K]. Metallomics. 2014;6(10):1816–1823.
   PubMed Web of Science ®Google Scholar
• Reaney S, Smith D. Manganese oxidation state mediates toxicity in PC12 cells. Toxicol Appl Pharmacol. 2005;205(3):271–281.
   PubMed Web of Science ®Google Scholar
• Dupont C, Tanaka Y. Blood manganese levels in children with convulsive disorder. Biochem Med. 1985;33(2):246–255.
   PubMedGoogle Scholar
• Kürekçi AE, Alpay F, Tanindi Ş, et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia. 1995;36(6):600–604.
   PubMed Web of Science ®Google Scholar
• Papavasiliou P, Miller ST. Generalized seizures alter the cerebral and peripheral metabolism of essential metals in mice. Exp Neurol. 1983;82(1):223–236.
   PubMed Web of Science ®Google Scholar
• Carl GF, Critchfield J, Thompson J, et al. Genetically epilepsy‐prone rats are characterized by altered tissue trace element concentrations. Epilepsia. 1990;31(3):247–252.
   PubMed Web of Science ®Google Scholar
• Couper J. Sur les effets du peroxide de manganèse. J Chim Méd Pharm Toxicol. 1837;3:223–225.
   Google Scholar
• Bowler RM, Gocheva V, Harris M, et al. Prospective study on neurotoxic effects in manganese-exposed bridge construction welders. Neurotoxicology. 2011 Oct;32(5):596–605. PubMed PMID: 21762725.
   PubMed Web of Science ®Google Scholar
• O’Neal SL, Zheng W. Manganese toxicity upon overexposure: a decade in review [journal article]. Curr Environ Health Rep. 2015;2(3):315–328.
   PubMedGoogle Scholar
• Bouabid S, Tinakoua A, Lakhdar‐Ghazal N, et al. Manganese neurotoxicity: behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmission. J Neurochem. 2016;136(4):677–691.
   PubMed Web of Science ®Google Scholar
• Kwakye GF, Paoliello MM, Mukhopadhyay S, et al. Manganese-induced parkinsonism and Parkinson’s Disease: shared and distinguishable features. Int J Environ Res Public Health. 2015 Jul 6;12(7):7519–7540. PubMed PMID: 26154659; PubMed Central PMCID: PMCPMC4515672.
   PubMed Web of Science ®Google Scholar
• Guilarte TR, Gonzales KK. Manganese-induced parkinsonism is not idiopathic Parkinson’s Disease: environmental and genetic evidence. Toxicol Sci. 2015 Aug;146(2):204–212. PubMed PMID: 26220508; PubMed Central PMCID: PMCPMC4607750.
   PubMed Web of Science ®Google Scholar
• Guilarte TR. Manganese and Parkinson’s disease: a critical review and new findings. Environ Health Perspect. 2010 Aug;118(8):1071–1080. PubMed PMID: 20403794; PubMed Central PMCID: PMC2920085. eng.
   PubMed Web of Science ®Google Scholar
• Bouabid S, Tinakoua A, Lakhdar-Ghazal N, et al. Manganese Neurotoxicity: behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmission. J Neurochem. 2015 Nov 26. PubMed PMID: 26608821. DOI:10.1111/jnc.13442
   PubMed Web of Science ®Google Scholar
• Cersosimo MG, Koller WC. The diagnosis of manganese-induced parkinsonism. Neurotoxicology. 2006 May;27(3):340–346. PubMed PMID: 16325915.
   PubMed Web of Science ®Google Scholar
• Chen P, Chakraborty S, Mukhopadhyay S, et al. Manganese homeostasis in the nervous system. J Neurochem. 2015 Aug;134(4):601–610. PubMed PMID: 25982296; PubMed Central PMCID: PMCPMC4516557.
   PubMed Web of Science ®Google Scholar
• Bowman AB, Kwakye GF, Herrero Hernandez E, et al. Role of manganese in neurodegenerative diseases. J Trace Elem Med Biol. 2011 Dec;25(4):191–203. PubMed PMID: 21963226; PubMed Central PMCID: PMC3230726.
   PubMed Web of Science ®Google Scholar
• Aschner M, Erikson KM, Herrero Hernandez E, et al. Manganese and its role in Parkinson’s disease: from transport to neuropathology. Neuromolecular Med. 2009;11(4):252–266. PubMed PMID: 19657747; PubMed Central PMCID: PMCPMC4613768.
   PubMed Web of Science ®Google Scholar
• Tuschl K, Mills PB, Clayton PT. Manganese and the brain. Int Rev Neurobiol. 2013;110:277–312. PubMed PMID: 24209443.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Tan X, Luo Y, et al. Relationship between blood levels of heavy metals and Parkinson’s disease in China. Neuroepidemiology. 2010;34(1):18–24. PubMed PMID: 19893325.
   PubMed Web of Science ®Google Scholar
• Hozumi I, Hasegawa T, Honda A, et al. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci. 2011 Apr 15;303(1–2):95–99. PubMed PMID: 21292280.
   PubMed Web of Science ®Google Scholar
• Racette BA, Criswell SR, Lundin JI, et al. Increased risk of parkinsonism associated with welding exposure. Neurotoxicology. 2012 Oct;33(5):1356–1361. PubMed PMID: 22975422.
   PubMed Web of Science ®Google Scholar
• Racette BA, Tabbal SD, Jennings D, et al. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology. 2005 Jan 25;64(2):230–235. PubMed PMID: 15668418; eng.
   PubMed Web of Science ®Google Scholar
• Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease. Neurotoxicology. 1999 Apr–Jun;20(2–3):239–247. PubMed PMID: 10385887; eng.
   PubMed Web of Science ®Google Scholar
• Mortimer JA, Borenstein AR, Nelson LM. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology. 2012 Sep 11;79:1174–1180. PubMed PMID: 22965675; PubMed Central PMCID: PMCPMC3525308.
   PubMed Web of Science ®Google Scholar
• Willis AW, Evanoff BA, Lian M, et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol. 2010 Dec 15;172(12):1357–1363. PubMed PMID: 20959505; PubMed Central PMCID: PMCPMC2998201.
   PubMed Web of Science ®Google Scholar
• Finkelstein MM, Jerrett M. A study of the relationships between Parkinson’s disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res. 2007 Jul;104(3):420–432. PubMed PMID: 17445792.
   PubMed Web of Science ®Google Scholar
• Palacios N, Fitzgerald K, Roberts AL, et al. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses’ health study cohort. Environ Health Perspect. 2014 Sep;122(9):933–938. PubMed PMID: 24905870; PubMed Central PMCID: PMCPMC4154211.
   PubMed Web of Science ®Google Scholar
• Roth JA. Correlation between the biochemical pathways altered by mutated parkinson-related genes and chronic exposure to manganese. Neurotoxicology. 2014 Sep;44:314–325. PubMed PMID: 25149416.
   PubMed Web of Science ®Google Scholar
• Chen P, Parmalee N, Aschner M. Genetic factors and manganese-induced neurotoxicity. Front Genet. 2014;5:265. PubMed PMID: 25136353; PubMed Central PMCID: PMCPMC4120679.
   PubMed Web of Science ®Google Scholar
• Wu CR, Tsai CW, Chang SW, et al. Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson’s disease: involvement of antioxidative enzymes induction. Chem Biol Interact. 2015 Jan;5(225):40–46. PubMed PMID: 25446857.
   PubMed Web of Science ®Google Scholar
• Higashi Y, Asanuma M, Miyazaki I, et al. Parkin attenuates manganese-induced dopaminergic cell death. J Neurochem. 2004 Jun;89(6):1490–1497. PubMed PMID: 15189352.
   PubMed Web of Science ®Google Scholar
• Tan J, Zhang T, Jiang L, et al. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. J Biol Chem. 2011 Aug 26;286(34):29654–29662. PubMed PMID: 21724849; PubMed Central PMCID: PMC3191006.
   PubMed Web of Science ®Google Scholar
• Rentschler G, Covolo L, Haddad AA, et al. ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese. Neurotoxicology. 2012 Aug;33(4):697–702. PubMed PMID: 22285144; PubMed Central PMCID: PMCPMC3997180.
   PubMed Web of Science ®Google Scholar
• Cai T, Yao T, Zheng G, et al. Manganese induces the overexpression of alpha-synuclein in PC12 cells via ERK activation. Brain Res. 2010 Nov 4;1359:201–207. PubMed PMID: 20735995.
   PubMed Web of Science ®Google Scholar
• Xu B, Liu W, Deng Y, et al. Inhibition of calpain prevents manganese-induced cell injury and alpha-synuclein oligomerization in organotypic brain slice cultures. PLoS One. 2015;10(3):e0119205. PubMed PMID: 25756858; PubMed Central PMCID: PMCPMC4355489.
   PubMed Web of Science ®Google Scholar
• Verina T, Schneider JS, Guilarte TR. Manganese exposure induces alpha-synuclein aggregation in the frontal cortex of non-human primates. Toxicol Lett. 2013 Mar 13;217(3):177–183. PubMed PMID: 23262390; PubMed Central PMCID: PMC3638947.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun L, Cai T, et al. alpha-Synuclein overexpression during manganese-induced apoptosis in SH-SY5Y neuroblastoma cells. Brain Res Bull. 2010 Mar 16;81(4––5):428–433. PubMed PMID: 19932157.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006 Feb;36(2):159–165. PubMed PMID: 16420712.
   PubMed Web of Science ®Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942–948. PubMed PMID: 17541055.
   PubMed Web of Science ®Google Scholar
• Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 2007 Jul;20(4):386–392. PubMed PMID: 17551354.
   PubMed Web of Science ®Google Scholar
• Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. 2007 Sep;96(9):1269–1274. PubMed PMID: 17718779.
   PubMed Web of Science ®Google Scholar
• Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006 Dec;114(12):1904–1909. PubMed PMID: 17185283; PubMed Central PMCID: PMCPMC1764142.
   PubMed Web of Science ®Google Scholar
• Kollins SH, Adcock RA. ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: implications for smoking and nicotine dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:70–78.
   PubMed Web of Science ®Google Scholar
• Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014 Feb;48(2):209–225. PubMed PMID: 24259638.
   PubMed Web of Science ®Google Scholar
• Farias AC, Cunha A, Benko CR, et al. Manganese in children with attention-deficit/hyperactivity disorder: relationship with methylphenidate exposure [Clinical Trial Research Support, Non-U.S. Gov’t]. J Child Adolesc Psychopharmacol. 2010 Apr;20(2):113–118. PubMed PMID: 20415606.
   PubMed Web of Science ®Google Scholar
• Yousef S, Adem A, Zoubeidi T, et al. Attention deficit hyperactivity disorder and environmental toxic metal exposure in the United Arab Emirates. J Trop Pediatr. 2011 Dec;57(6):457–460. PubMed PMID: 21300623.
   PubMed Web of Science ®Google Scholar
• Liu W, Huo X, Liu D, et al. S100beta in heavy metal-related child attention-deficit hyperactivity disorder in an informal e-waste recycling area. Neurotoxicology. 2014 Dec;45:185–191. PubMed PMID: 25451971.
   PubMed Web of Science ®Google Scholar
• Bouchard M, Laforest F, Vandelac L, et al. Hair manganese and hyperactive behaviors: pilot study of school-age children exposed through tap water. Environ Health Perspect. 2007 Jan;115(1):122–127. PubMed PMID: 17366831; PubMed Central PMCID: PMCPMC1797845.
   PubMed Web of Science ®Google Scholar
• Oulhote Y, Mergler D, Barbeau B, et al. Neurobehavioral function in school-age children exposed to manganese in drinking water. Environ Health Perspect. 2014 Dec;122(12):1343–1350. PubMed PMID: 25260096; PubMed Central PMCID: PMCPMC4256698.
   PubMed Web of Science ®Google Scholar
• Khan K, Factor-Litvak P, Wasserman GA, et al. Manganese exposure from drinking water and children’s classroom behavior in Bangladesh. Environ Health Perspect. 2011 Oct;119(10):1501–1506. PubMed PMID: 21493178; PubMed Central PMCID: PMCPMC3230445.
   PubMed Web of Science ®Google Scholar
• Ericson JE, Crinella FM, Clarke-Stewart KA, et al. Prenatal manganese levels linked to childhood behavioral disinhibition. Neurotoxicol Teratol. 2007 Mar–Apr;29(2):181–187. PubMed PMID: 17079114.
   PubMed Web of Science ®Google Scholar
• Chan TJ, Gutierrez C, Ogunseitan OA. Metallic burden of deciduous teeth and childhood behavioral deficits. Int J Environ Res Public Health. 2015 Jun 15;12(6):6771–6787. PubMed PMID: 26084001; PubMed Central PMCID: PMCPMC4483729.
   PubMed Web of Science ®Google Scholar
• Lucchini RG, Zoni S, Guazzetti S, et al. Inverse association of intellectual function with very low blood lead but not with manganese exposure in Italian adolescents. Environ Res. 2012 Oct;118:65–71. PubMed PMID: 22925625; PubMed Central PMCID: PMCPMC3477579.
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007 Mar;64(3):327–337. PubMed PMID: 17339521.
   PubMed Web of Science ®Google Scholar
• Andrews PW, Bharwani A, Lee KR, et al. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci Biobehav Rev. 2015 Apr;51:164–188. PubMed PMID: 25625874.
   PubMed Web of Science ®Google Scholar
• Bowler RM, Gysens S, Diamond E, et al. Manganese exposure: neuropsychological and neurological symptoms and effects in welders. Neurotoxicology. 2006 May;27(3):315–326. PubMed PMID: 16343629.
   PubMed Web of Science ®Google Scholar
• Bouchard M, Mergler D, Baldwin M, et al. Neuropsychiatric symptoms and past manganese exposure in a ferro-alloy plant. Neurotoxicology. 2007 Mar;28(2):290–297. PubMed PMID: 16962176.
   PubMed Web of Science ®Google Scholar
• Bowler RM, Roels HA, Nakagawa S, et al. Dose-effect relationships between manganese exposure and neurological, neuropsychological and pulmonary function in confined space bridge welders. Occup Environ Med. 2007 Mar;64(3):167–177. PubMed PMID: 17018581; PubMed Central PMCID: PMCPMC2092523.
   PubMed Web of Science ®Google Scholar
• Yuan H, He S, He M, et al. A comprehensive study on neurobehavior, neurotransmitters and lymphocyte subsets alteration of Chinese manganese welding workers. Life Sci. 2006 Feb 16;78(12):1324–1328. PubMed PMID: 16243361.
   PubMed Web of Science ®Google Scholar
• Shiue I. Urinary heavy metals, phthalates and polyaromatic hydrocarbons independent of health events are associated with adult depression: USA NHANES, 2011-2012. Environ Sci Pollut Res Int. 2015 Nov;22(21):17095–17103. 10.1007/s11356-015-4944-2. PubMed PMID: 26126689.
   PubMed Web of Science ®Google Scholar
• Zheng W, Fu SX, Dydak U, et al. Biomarkers of manganese intoxication. Neurotoxicology. 2011 Jan;32(1):1–8. PubMed PMID: 20946915; PubMed Central PMCID: PMCPMC3030659.
   PubMed Web of Science ®Google Scholar
• Abdalian R, Saqui O, Fernandes G, et al. Effects of manganese from a commercial multi-trace element supplement in a population sample of Canadian patients on long-term parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013 Jul;37(4):538–543. PubMed PMID: 22829428.
   PubMed Web of Science ®Google Scholar
• Hong SB, Kim JW, Choi BS, et al. Blood manganese levels in relation to comorbid behavioral and emotional problems in children with attention-deficit/hyperactivity disorder. Psychiatry Res. 2014 Dec 15;220(1–2):418–425. PubMed PMID: 25064383.
   PubMed Web of Science ®Google Scholar
• Rubio-Lopez N, Morales-Suarez-Varela M, Pico Y, et al. Nutrient intake and depression symptoms in spanish children: the ANIVA study. Int J Environ Res Public Health. 2016 Mar 22;13(3). PubMed PMID: 27011198; PubMed Central PMCID: PMCPMC4809015. DOI:10.3390/ijerph13030352
   PubMed Web of Science ®Google Scholar
• Miyake Y, Tanaka K, Okubo H, et al. Manganese intake is inversely associated with depressive symptoms during pregnancy in Japan: baseline data from the Kyushu Okinawa maternal and child health study. J Affect Disord. 2017 Mar 15;211:124–129. PubMed PMID: 28110159.
   PubMed Web of Science ®Google Scholar
• Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol. 2008 Oct;29(9):1612–1621. PubMed PMID: 18583413.
   PubMed Web of Science ®Google Scholar
• Ciecko-Michalska I, Szczepanek M, Slowik A, et al. Pathogenesis of hepatic encephalopathy. Gastroenterol Res Pract. 2012;2012:642108. PubMed PMID: 23316223; PubMed Central PMCID: PMCPMC3534214.
   PubMedGoogle Scholar
• Ferro JM, Oliveira S. Neurologic manifestations of gastrointestinal and liver diseases. Curr Neurol Neurosci Rep. 2014 Oct;14(10):487. PubMed PMID: 25171900.
   PubMed Web of Science ®Google Scholar
• Cordoba J. Hepatic encephalopathy: from the pathogenesis to the new treatments. ISRN Hepatol. 2014;2014:236268. PubMed PMID: 27335836; PubMed Central PMCID: PMCPMC4890879.
   PubMedGoogle Scholar
• Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology. 1999 Sep;117(3):640–644. PubMed PMID: 10464140.
   PubMed Web of Science ®Google Scholar
• Zeron HM, Rodriguez MR, Montes S, et al. Blood manganese levels in patients with hepatic encephalopathy. J Trace Elem Med Biol. 2011 Dec;25(4):225–229. PubMed PMID: 21975221.
   PubMed Web of Science ®Google Scholar
• Burkhard PR, Delavelle J, Du Pasquier R, et al. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003 Apr;60(4):521–528. PubMed PMID: 12707065.
   PubMedGoogle Scholar
• Spahr L, Butterworth RF, Fontaine S, et al. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology. 1996 Nov;24(5):1116–1120. PubMed PMID: 8903385.
   PubMed Web of Science ®Google Scholar
• Layrargues GP, Shapcott D, Spahr L, et al. Accumulation of manganese and copper in pallidum of cirrhotic patients: role in the pathogenesis of hepatic encephalopathy? Metab Brain Dis. 1995 Dec;10(4):353–356. PubMed PMID: 8847998.
   PubMed Web of Science ®Google Scholar
• Butterworth RF. Metal toxicity, liver disease and neurodegeneration. Neurotox Res. 2010 Jul;18(1):100–105. PubMed PMID: 20369313.
   PubMed Web of Science ®Google Scholar
• Alonso J, Cordoba J, Rovira A. Brain magnetic resonance in hepatic encephalopathy. Semin Ultrasound CT MR. 2014 Apr;35(2):136–152. PubMed PMID: 24745889.
   PubMed Web of Science ®Google Scholar
• Butterworth RF. Pathophysiology of hepatic encephalopathy: the concept of synergism. Hepatol Res. 2008 Nov;38(Suppl 1):S116–21. PubMed PMID: 19125942.
   PubMedGoogle Scholar
• Salgado M, Cortes Y. Hepatic encephalopathy: etiology, pathogenesis, and clinical signs. Compend Contin Educ Vet. 2013 Jun;35(6):E1–8. quiz E9. PubMed PMID: 23677822.
   Google Scholar
• Ahboucha S. Neurosteroids and hepatic encephalopathy: an update on possible pathophysiologic mechanisms. Curr Mol Pharmacol. 2011 Jan;4(1):1–13. PubMed PMID: 20825363.
   PubMedGoogle Scholar
• Savlan I, Liakina V, Valantinas J. Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy. Medicina (Kaunas). 2014;502:75–81. PubMed PMID: 25172600.
   PubMed Web of Science ®Google Scholar
• Cichoz-Lach H, Michalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. World J Gastroenterol. 2013 Jan 7;19(1):26–34. PubMed PMID: 23326159; PubMed Central PMCID: PMCPMC3545226.
   PubMed Web of Science ®Google Scholar
• Butterworth RF. Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited. Metab Brain Dis. 2016 Dec;31(6):1211–1215. PubMed PMID: 26521983.
   PubMed Web of Science ®Google Scholar
• Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010 Sep;7(9):515–525. PubMed PMID: 20703237.
   PubMed Web of Science ®Google Scholar
• Aschner JL, Aschner M. Nutritional aspects of manganese homeostasis. Mol Aspects Med. 2005 Aug–Oct;26(4–5):353–362. PubMed PMID: 16099026.
   PubMedGoogle Scholar
• Smith D, Gwiazda R, Bowler R, et al. Biomarkers of Mn exposure in humans. Am J Ind Med. 2007 Nov;50(11):801–811. PubMed PMID: 17924418.
   PubMed Web of Science ®Google Scholar
• Schroeter JD, Nong A, Yoon M, et al. Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. Toxicol Sci. 2011 Apr;120(2):481–498. PubMed PMID: 21205636.
   PubMed Web of Science ®Google Scholar
• Ntihabose R, Surette C, Foucher D, et al. Assessment of saliva, hair and toenails as biomarkers of low level exposure to manganese from drinking water in children. Neurotoxicology. 2018 Jan;64:126–133. PubMed PMID: 28867366.
   PubMed Web of Science ®Google Scholar
• Grashow R, Zhang J, Fang SC, et al. Toenail metal concentration as a biomarker of occupational welding fume exposure. J Occup Environ Hyg. 2014;11(6):397–405. PubMed PMID: 24372360; PubMed Central PMCID: PMCPMC4019688.
   PubMed Web of Science ®Google Scholar
• Viana GF, de Carvalho CF, Nunes LS, et al. Noninvasive biomarkers of manganese exposure and neuropsychological effects in environmentally exposed adults in Brazil. Toxicol Lett. 2014 Dec 1;231(2):169–178. PubMed PMID: 24992226.
   PubMed Web of Science ®Google Scholar
• Menezes-Filho JA, Paes CR, Pontes AM, et al. High levels of hair manganese in children living in the vicinity of a ferro-manganese alloy production plant. Neurotoxicology. 2009 Nov;30(6):1207–1213. PubMed PMID: 19393689; PubMed Central PMCID: PMCPMC2789903.
   PubMed Web of Science ®Google Scholar
• Reiss B, Simpson CD, Mg B, et al. Hair manganese as an exposure biomarker among welders. Ann Occup Hyg. 2016 Mar;60(2):139–149. PubMed PMID: 26409267; PubMed Central PMCID: PMCPMC4834832.
   PubMedGoogle Scholar
• Cowan DM, Fan Q, Zou Y, et al. Manganese exposure among smelting workers: blood manganese-iron ratio as a novel tool for manganese exposure assessment. Biomarkers. 2009 Feb;14(1):3–16. PubMed PMID: 19283519; PubMed Central PMCID: PMCPMC3980868.
   PubMed Web of Science ®Google Scholar
• Cowan DM, Zheng W, Zou Y, et al. Manganese exposure among smelting workers: relationship between blood manganese-iron ratio and early onset neurobehavioral alterations. Neurotoxicology. 2009 Nov;30(6):1214–1222. PubMed PMID: 19963104; PubMed Central PMCID: PMCPMC3983997.
   PubMed Web of Science ®Google Scholar
• Tutkun E, Abusoglu S, Yilmaz H, et al. Prolactin levels in manganese-exposed male welders. Pituitary. 2014 Dec;17(6):564–568. PubMed PMID: 24337778.
   PubMed Web of Science ®Google Scholar
• Montes S, Schilmann A, Riojas-Rodriguez H, et al. Serum prolactin rises in Mexican school children exposed to airborne manganese. Environ Res. 2011 Nov;111(8):1302–1308. PubMed PMID: 22001219.
   PubMed Web of Science ®Google Scholar
• Smargiassi A, Mutti A. Peripheral biomarkers and exposure to manganese. Neurotoxicology. 1999 Apr–Jun;20(2–3):401–406. PubMed PMID: 10385899.
   PubMed Web of Science ®Google Scholar
• Montes S, Riojas-Rodriguez H, Sabido-Pedraza E, et al. Biomarkers of manganese exposure in a population living close to a mine and mineral processing plant in Mexico. Environ Res. 2008 Jan;106(1):89–95. PubMed PMID: 17915211.
   PubMed Web of Science ®Google Scholar
• Kim EA, Cheong HK, Joo KD, et al. Effect of manganese exposure on the neuroendocrine system in welders. Neurotoxicology. 2007 Mar;28(2):263–269. PubMed PMID: 16950514.
   PubMed Web of Science ®Google Scholar
• Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000 Oct;80(4):1523–1631. PubMed PMID: 11015620.
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee CK, Lee JT, et al. Effects of manganese exposure on dopamine and prolactin production in rat. Neuroreport. 2009 Jan 7;20(1):69–73. PubMed PMID: 19057282.
   PubMed Web of Science ®Google Scholar
• Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed. 2004 Dec;17(8):544–553. PubMed PMID: 15617053; PubMed Central PMCID: PMCPMC3980863.
   PubMed Web of Science ®Google Scholar
• Fell JM, Reynolds AP, Meadows N, et al. Manganese toxicity in children receiving long-term parenteral nutrition. Lancet. 1996 May 4;347(9010):1218–1221. PubMed PMID: 8622451.
   PubMed Web of Science ®Google Scholar
• Bowler RM, Yeh CL, Adams SW, et al. Association of MRI T1 relaxation time with neuropsychological test performance in manganese- exposed welders. Neurotoxicology. 2018 Jan;64:19–29. PubMed PMID: 28587807; PubMed Central PMCID: PMCPMC5905426.
   PubMed Web of Science ®Google Scholar
• Criswell SR, Perlmutter JS, Huang JL, et al. Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders. Occup Environ Med. 2012 Jun;69(6):437–443. PubMed PMID: 22447645.
   PubMed Web of Science ®Google Scholar
• Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet. 1995 Jul 29;346(8970):270–274. PubMed PMID: 7630246.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zheng W, Long L, et al. Brain magnetic resonance imaging and manganese concentrations in red blood cells of smelting workers: search for biomarkers of manganese exposure. Neurotoxicology. 2007 Jan;28(1):126–135. PubMed PMID: 16978697; PubMed Central PMCID: PMCPMC3983995.
   PubMed Web of Science ®Google Scholar
• Long Z, Jiang YM, Li XR, et al. Vulnerability of welders to manganese exposure–a neuroimaging study. Neurotoxicology. 2014 Dec;45:285–292. PubMed PMID: 24680838; PubMed Central PMCID: PMCPMC4177505.
   PubMed Web of Science ®Google Scholar
• Dorman DC, Struve MF, Wong BA, et al. Correlation of brain magnetic resonance imaging changes with pallidal manganese concentrations in rhesus monkeys following subchronic manganese inhalation. Toxicol Sci. 2006 Jul;92(1):219–227. PubMed PMID: 16638924.
   PubMed Web of Science ®Google Scholar
• Lee EY, Flynn MR, Du G, et al. T1 relaxation rate (R1) indicates nonlinear mn accumulation in brain tissue of welders with low-level exposure. Toxicol Sci. 2015 Aug;146(2):281–289. PubMed PMID: 25953701; PubMed Central PMCID: PMCPMC4607746.
   PubMed Web of Science ®Google Scholar
• Choi DS, Kim EA, Cheong HK, et al. Evaluation of MR signal index for the assessment of occupational manganese exposure of welders by measurement of local proton T1 relaxation time. Neurotoxicology. 2007 Mar;28(2):284–289. PubMed PMID: 16828869.
   PubMed Web of Science ®Google Scholar
• Sikk K, Haldre S, Aquilonius SM, et al. Manganese-induced parkinsonism due to ephedrone abuse. Parkinsons Dis. 2011;2011:865319. PubMed PMID: 21403909; PubMed Central PMCID: PMC3043321.
   PubMedGoogle Scholar
• Kim Y, Kim KS, Yang JS, et al. Increase in signal intensities on T1-weighted magnetic resonance images in asymptomatic manganese-exposed workers. Neurotoxicology. 1999 Dec;20(6):901–907. PubMed PMID: 10693971.
   PubMed Web of Science ®Google Scholar
• Kim Y. Neuroimaging in manganism. Neurotoxicology. 2006 May;27(3):369–372. PubMed PMID: 16442160.
   PubMed Web of Science ®Google Scholar
• Kim EA, Cheong HK, Choi DS, et al. Effect of occupational manganese exposure on the central nervous system of welders: 1H magnetic resonance spectroscopy and MRI findings. Neurotoxicology. 2007 Mar;28(2):276–283. PubMed PMID: 16824604.
   PubMed Web of Science ®Google Scholar
• Chang Y, Woo ST, Lee JJ, et al. Neurochemical changes in welders revealed by proton magnetic resonance spectroscopy. Neurotoxicology. 2009 Nov;30(6):950–957. PubMed PMID: 19631686.
   PubMed Web of Science ®Google Scholar
• Dydak U, Jiang YM, Long LL, et al. In vivo measurement of brain GABA concentrations by magnetic resonance spectroscopy in smelters occupationally exposed to manganese. Environ Health Perspect. 2011 Feb;119(2):219–224. PubMed PMID: 20876035; PubMed Central PMCID: PMCPMC3040609.
   PubMed Web of Science ®Google Scholar
• O’Neal SL, Zheng W. Manganese toxicity upon overexposure: a decade in review. Curr Environ Health Rep. 2015 Sep;2(3):315–328. PubMed PMID: 26231508; PubMed Central PMCID: PMCPMC4545267.
   PubMedGoogle Scholar
• Walter E, Alsaffar S, Livingstone C, et al. Manganese toxicity in critical care: case report, literature review and recommendations for practice. J Intensive Care Soc. 2016 Aug;17(3):252–257. PubMed PMID: 28979499; PubMed Central PMCID: PMCPMC5606512.
   PubMedGoogle Scholar
• Koller WC, Lyons KE, Truly W. Effect of levodopa treatment for parkinsonism in welders: a double-blind study. Neurology. 2004 Mar 9;62(5):730–733. PubMed PMID: 15007122.
   PubMed Web of Science ®Google Scholar
• Discalzi G, Pira E, Herrero Hernandez E, et al. Occupational Mn parkinsonism: magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation. Neurotoxicology. 2000 Oct;21(5):863–866. PubMed PMID: 11130292.
   PubMed Web of Science ®Google Scholar
• Ono K, Komai K, Yamada M. Myoclonic involuntary movement associated with chronic manganese poisoning. J Neurol Sci. 2002 Jul 15;199(1–2):93–96. PubMed PMID: 12084450.
   PubMed Web of Science ®Google Scholar
• Quadri M, Federico A, Zhao T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012 Mar 9;90(3):467–477. PubMed PMID: 22341971; PubMed Central PMCID: PMCPMC3309204.
   PubMed Web of Science ®Google Scholar
• Jiang YM, Mo XA, Du FQ, et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. J Occup Environ Med. 2006 Jun;48(6):644–649. PubMed PMID: 16766929; PubMed Central PMCID: PMCPMC4180660.
   PubMed Web of Science ®Google Scholar
• Zheng W, Jiang YM, Zhang Y, et al. Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats. Neurotoxicology. 2009 Mar;30(2):240–248. PubMed PMID: 19150464; PubMed Central PMCID: PMCPMC2677987.
   PubMed Web of Science ®Google Scholar
• Tuschl K, Mills PB, Parsons H, et al. Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia–a new metabolic disorder. J Inherit Metab Dis. 2008 Apr;31(2):151–163. PubMed PMID: 18392750.
   PubMed Web of Science ®Google Scholar